trending Market Intelligence /marketintelligence/en/news-insights/trending/tvm3ynqq-16jduulauwjka2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

NYSE accepts CorMedix's plan to regain compliance with listing requirements

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


NYSE accepts CorMedix's plan to regain compliance with listing requirements

CorMedix Inc. said the New York Stock Exchange accepted its plan to regain compliance with its listing requirements.

The Brisbane, Calif.-based company had said in June that it received a noncompliance notice from the NYSE American.

The biopharmaceutical company had reported a stockholders' equity of $800,000, lower than a minimum of $2 million as required by NYSE.

CorMedix, which submitted its plan on July 16, has until Dec. 16, 2019 to regain compliance.